Waters (WAT) Valuation Check After Recent 3-Month Share Price Rebound

Simply Wall St.2025-12-17

Waters (WAT) has quietly outpaced the broader market over the past 3 months, and with revenue and net income both growing solidly, investors are starting to revisit what they are actually paying for. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592964724?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2025-12-17 13:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592964724","market":"us","top_or_hot":-1,"title":"Waters (WAT) Valuation Check After Recent 3-Month Share Price Rebound","media":"Simply Wall St.","content":"<div>\n<p>Waters (WAT) has quietly outpaced the broader market over the past 3 months, and with revenue and net income both growing solidly, investors are starting to revisit what they are actually paying for. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-wat/waters/news/waters-wat-valuation-check-after-recent-3-month-share-price\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Waters (WAT) Valuation Check After Recent 3-Month Share Price Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWaters (WAT) Valuation Check After Recent 3-Month Share Price Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-17 13:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-wat/waters/news/waters-wat-valuation-check-after-recent-3-month-share-price><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Waters (WAT) has quietly outpaced the broader market over the past 3 months, and with revenue and net income both growing solidly, investors are starting to revisit what they are actually paying for. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-wat/waters/news/waters-wat-valuation-check-after-recent-3-month-share-price\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-wat/waters/news/waters-wat-valuation-check-after-recent-3-month-share-price","article_id":"2592964724","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-wat/waters/news/waters-wat-valuation-check-after-recent-3-month-share-price","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2592964724","pubTimestamp":1765949131,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Waters (WAT) has quietly outpaced the broader market over the past 3 months, and with revenue and net income both growing solidly, investors are starting to revisit what they are actually paying for.\nSee our latest analysis for Waters.\nOver the past year, Waters’ share price has been choppy, but its roughly 25 percent 3 month share price return suggests momentum is rebuilding as investors reassess both its growth runway and perceived risk profile around the 378.53 dollar level.\nIf Waters’...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","GB00B4QBRK32.GBP":"FUNDSMITH EQUITY \"R\" (GBP) INC","WAT.AU":"WATERCO LIMITED","LU0347712357.USD":"BNP PARIBAS GLOBAL ENVIRONMENT \"C\" (USD) ACC","LU0690374961.EUR":"FUNDSMITH EQUITY \"R\" (EUR) INC","GB00B4LPDJ14.GBP":"FUNDSMITH EQUITY \"R\" (GBP) ACC","LU2404859741.USD":"FUNDSMITH EQUITY FUND \"R\" (USD) INC","LU1721428933.USD":"法巴全球经典环境基金RH MD Dis","LU2413666426.HKD":"BNP PARIBAS GLOBAL ENVIRONMENT \"C\" (HKD) ACC","BK4588":"碎股","LU0690374615.EUR":"FUNDSMITH EQUITY \"R\" (EUR) ACC","WAT":"沃特世","BK4585":"ETF&股票定投概念","BK7118":"消闲用品","LU2413666699.HKD":"BNP PARIBAS GLOBAL ENVIRONMENT \"CRH\" (HKDHDG) INC","LU2404859667.USD":"FUNDSMITH EQUITY FUND \"R\" (USD) ACC"},"translate_title":"沃特世(WAT)最近3个月股价反弹后的估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WAT.AU":1.5,"WAT":1.5},"content_text":"Waters (WAT) has quietly outpaced the broader market over the past 3 months, and with revenue and net income both growing solidly, investors are starting to revisit what they are actually paying for. See our latest analysis for Waters. Over the past year, Waters’ share price has been choppy, but its roughly 25 percent 3 month share price return suggests momentum is rebuilding as investors reassess both its growth runway and perceived risk profile around the 378.53 dollar level. If Waters’ recent move has caught your attention, this could be a good moment to explore other specialist healthcare names using our curated screen of healthcare stocks for fresh ideas. With earnings humming, a near 30 percent intrinsic discount implied by our model, and shares only modestly below analyst targets, the real question is whether Waters is still mispriced or if the market already anticipates its next leg of growth. Most Popular Narrative Narrative: 4.1% Undervalued With Waters last closing at 378.53 dollars against a narrative fair value near 395 dollars, the story leans toward modest upside driven by earnings power.  The fair value estimate has risen slightly to approximately 395 dollars per share from about 389 dollars per share, reflecting modest valuation upside. The future P/E has risen modestly from about 29.6x to roughly 30.1x, implying a slightly higher expected valuation multiple on forward earnings.  Read the complete narrative. Curious why a mature lab instruments business is being priced with growth style assumptions on margins and future earnings power. Want to see which forecasts justify that confidence. Result: Fair Value of $394.68 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, lingering integration risks around the BD assets and weaker academic and pharma funding could easily derail the margin and earnings trajectory underpinning this valuation. Find out about the key risks to this Waters narrative.  Build Your Own Waters Narrative If this perspective does not quite match your own or you would rather dig into the numbers yourself, you can craft a tailored view in just minutes: Do it your way. A great starting point for your Waters research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision. Looking for more investment ideas? Do not stop with one opportunity. Use Simply Wall Street's powerful screener tools to spot your next move before the market catches on.  Capture early stage growth potential by tracking these 3625 penny stocks with strong financials that already back up their promise with solid balance sheets and improving fundamentals. Position yourself at the forefront of automation and analytics advances by reviewing these 25 AI penny stocks that are building real businesses on top of AI innovation. Lock in income opportunities by targeting these 13 dividend stocks with yields > 3% that combine attractive yields with sustainable payout ratios and resilient cash flows.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.The New Payments ETF Is Live on NASDAQ:Money is moving to real-time rails, and a newly listed ETF now gives investors direct exposure. Fast settlement. Institutional custody. Simple access.Explore how this launch could reshape portfoliosSponsored ContentValuation is complex, but we're here to simplify it.Discover if Waters might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592964724","isCrawlerRequest":true}